• email inquiry@market.us
  • phone+1 718 618 4351 (International)
  • phone+91 78878 22626 (Asia)
menu logo logo
more_vert
  • About Us
  • Contact Us
  • Our Team
  • Privacy Policy
July 8, 2021

Home / The Pfizer BioNTech Vaccine and its Impact On the Delta COVID-19 Variant

The Pfizer BioNTech Vaccine and its Impact On the Delta COVID-19 Variant

Kathleen Kinder

Last updated on:July 8, 2021 Market.us

While the further threat of contagion caused by the second-wave of COVID-19 may be regressing, the gradual emergence of variant strains of this virus have begun to be registered across numerous nations worldwide. None more so than the Delta variant. Going by information presented by Israeli website Ynet, there are pros and cons to being inoculated with the Pfizer BioNTech vaccine. This vaccine is one of three that have received approval for usage in the United States. The initial efficacy rate of this given vaccine against prior variants stood at 98.2% However, data published by the Israel Health Ministry between the 6th of June and 3rd of July, 2021, indicate that the vaccine now has an efficacy rate of 93% against the Delta variant.

While that may sound great, the bad news comes in the form of this vaccine now possessing an efficacy rate of just 64%, with respect to preventing overall infection. What this implies is that, even if an individual were to be completely vaccinated (i.e., have had both their required doses administered), they could still potentially catch this virus and exhibit corresponding symptoms. That has always been the case, however, the Delta variant of this virus increases the likelihood of that outcome.

The silver lining to this is that being inoculated greatly lowers an individual’s chances of being hospitalized, if at least not developing life-threatening symptoms as a result of being infected with this virus. The Delta variant of this virus is steadily gaining prominence as the dominant strain, with a growing number of cases being reported each day across the world. The third-anticipated wave of this pandemic is almost upon us, and healthcare facilities worldwide are bracing for an even more strenuous phase that is sure to leave these healthcare systems worse for wear.

Kathleen Kinder

With over 4 years of experience in the research industry, Kathleen is generally engrossed in market consulting projects, catering primarily to domains such as ICT, Health & Pharma, and packaging. She is highly proficient in managing both B2C and B2B projects, with an emphasis on consumer preference analysis, key executive interviews, etc. When Kathleen isn’t deconstructing market performance trajectories, she can be found hanging out with her pet cat ‘Sniffles’.

Share this:

  • Twitter
  • Facebook
  • LinkedIn

  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 618 4351 (International)
  • phone+91 78878 22626 (Asia)
  • emailinquiry@market.us

Find Help

  • Contact Us

Legal

  • Our Team
  • Privacy Policy

Explore

  • Technology
  • Business
  • News
  • Health
  • Science
  • Economy
  • Featured

Secured Payment Options

PayPal Payment System
Payoneer Payment System

© 2022 Market.us. All Rights Reserved.